Lenalidomide in multiple myeloma

References

• Brioli A, Melchor L, Walker BA, et al. Biology and treatment of myeloma. Clin Lymphoma Myeloma Leuk 2014;14:65-70
   Google Scholar
• Holstein SA, Liu H, McCarthy PL. Multiple myeloma. Hematol Oncol Clin North Am 2014;28:1113-29
   PubMedGoogle Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. The aspire investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372(2):142-52
   PubMed Web of Science ®Google Scholar
• Yordanova A, Hose D, Neben K, et al. Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol 2013;31:197-200
   PubMed Web of Science ®Google Scholar
• Kim Y, Gast SM, Endo T, et al. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma. Leuk Res 2012;36:598-600
   PubMedGoogle Scholar
• Kim Y, Schmidt M, Endo T, et al. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 2011;25:887-93
   PubMed Web of Science ®Google Scholar
• Schmidt M, Kim Y, Gast SM, et al. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo 2011;25:325-33
   PubMed Web of Science ®Google Scholar
• Kim Y, Alpmann P, Blaum-Feder S, et al. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 2011;25:99-103
   PubMed Web of Science ®Google Scholar
• Kim Y, Alpmann P, Blaum-Feder S, et al. In vivo efficacy of griseofulvin against multiple myeloma. Leuk Res 2011;35:1070-3
   PubMed Web of Science ®Google Scholar
• Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:999-1009
   PubMedGoogle Scholar
• Al-Mansour Z, Ramanathan M. Post-autologous (ASCT) stem cell transplant therapy in multiple myeloma. Adv Hematol 2014;2014:652395
   PubMedGoogle Scholar
• San Miguel JF. Relapse/refractory myeloma patient: potential treatment guidelines. J Clin Oncol 2009;27:5676-7
   PubMed Web of Science ®Google Scholar
• Bensinger W. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am 2014;28:891-902
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-67
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rocci A, Ludwig H, et al. Lenalidomide for multiple myeloma: Dr Palumbo and colleagues reply. N Engl J Med 2012;367:573-5
   PubMedGoogle Scholar
• Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738-44
   PubMed Web of Science ®Google Scholar
• Shank BR, Brown VT, Schwartz RN. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment. J Oncol Pharm Pract 2015;21:36-51
   PubMedGoogle Scholar
• Spina F, Montefusco V, Cripa C, et al. Lenalidomide can induce long term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leuk Lymphoma 2011;52:1262-70
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738-44
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69
   PubMed Web of Science ®Google Scholar
• Olszewska-Szopa M, Rzepecki P. Consolidation in multiple myeloma current status and perspectives. Contemp Oncol 2014;18:313-17
   Google Scholar
• Seiffert M. Lenalidomide, an antiproliferative CLL drug. Blood 2014;124:1545-6
   PubMed Web of Science ®Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014;15:1311-18
   PubMed Web of Science ®Google Scholar
• Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood 2014;124:2793-803
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Brady H, et al. Lenalidomide inhibits the multiple myeloma cell survival factor IRF4/MUM1. Clin Lymphoma Myeloma 2009;9:abstract 309
   Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
   PubMed Web of Science ®Google Scholar
• Marriott JB, Clarke IA, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF- and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin Exp Immunol 2002;130:75-84
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56-63
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-21
   PubMed Web of Science ®Google Scholar
• Noonan K, Rudraraju L, Ferguson A, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 2012;18:1426-34
   PubMed Web of Science ®Google Scholar
• Chang XB, Stewart AK. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol 2011;2:287-94
   PubMedGoogle Scholar
• Jonasova A, Bokorova R, Polak J, et al. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Eur J Haematol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9
   PubMed Web of Science ®Google Scholar
• Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 2014;21:803-909
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on dialysis. J Clin Pharmacol 2007;47:1466-75
   PubMed Web of Science ®Google Scholar
• Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk 2014; pii:2152-650.
   Google Scholar
• Klein U, Neben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol 2011;90:429-39
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Lonial S. Novel drug combinations for the management of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2014;14:71-7
   Google Scholar
• Dimopoulos MA, Swern AS, Li JS, et al. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J 2014;4:e257
   Google Scholar
• Koeppen S. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy. Oncol Res Treat 2014;37:506-13
   PubMed Web of Science ®Google Scholar
• Spina F, Montefusco V, Cripa C, et al. Lenalidomide can induce long term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leuk Lymphoma 2011;52:1262-70
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA Trial. J Clin Oncol 2010;28:2259-66
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Terpos E, Kleber M, et al. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014;99:232-42
   PubMed Web of Science ®Google Scholar
• Hasskarl J, Ihorst G, De Pasquale D, et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma 2011;52:247-59
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749-60
   PubMed Web of Science ®Google Scholar
• Zagouri F, Kastritis E, Gavriatopoulou M, et al. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma 2014;55:2018-23
   PubMed Web of Science ®Google Scholar
• Royer B, Merlusca L, Abraham J, et al. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 2013;88:207-12
   PubMed Web of Science ®Google Scholar
• Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933-9
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Terpos E, Kleber M, et al. European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014;99:232-42
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Laubach J, Anderson KC, et al. Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood 2013;121:858
   PubMed Web of Science ®Google Scholar
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595-608
   PubMed Web of Science ®Google Scholar
• Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-95
   PubMed Web of Science ®Google Scholar
• Dores GM, Cote TR, Travis L. New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. In: Curtis RE, Freedman DM, Ron E, et al. Editors. New malignancies among cancer survivors: SEER Cancer Registries 1973–2000. NIH Publ. No. 05-5302. National Cancer Institute, Bethesda, MD; 2006
   Google Scholar
• San Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11:38-43
   PubMed Web of Science ®Google Scholar
• Hamano A, Shingaki S, Abe Y, et al. Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia. Rinsho Ketsueki 2014;55(4):428-35
   PubMedGoogle Scholar
• Bwire R, Freeman J, Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opin Drug Saf 2011;10:3-8
   PubMed Web of Science ®Google Scholar
• Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838-41
   PubMed Web of Science ®Google Scholar
• Schwamborn K, Gorschlüter M, Glasmacher A, et al. Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. Ger Med Sci 2011; 9:Doc26
   Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28:525-42
   PubMed Web of Science ®Google Scholar
• Nooka AK. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology 2013;3:11-18
   Google Scholar
• Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015;12:42-54
   PubMed Web of Science ®Google Scholar
• Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122:3122-8
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RW, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar